Benitec Biopharma Inc.
For the period ended May 14, 2026. Filed May 14, 2026.
View on SEC.govAbout this filing
A notice of a major event between regular reports, such as results, a deal or a change of executives. It is often the first formal record of the news.
May 14, 2026 · Filed May 14, 2026
Use the contents to explore the available documents and sections.
Contents
EX-99.1 · BB-301 Development Program Updates
BB-301 Development Program Updates
All six Cohort 1 patients have safely completed the 12-month post-BB-301-treatment follow-up period and continue to experience robust responses to the low dose of BB-301.
The first two Cohort 2 patients have been safely treated with the high dose of BB-301, and available interim clinical results continue to demonstrate deep, disease-modifying efficacy for the high dose of BB-301.
No treatment-related severe adverse events have been observed.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.